PD98059

Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 128 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 Ml;0SpVv[3Srb36gRZN{[Xl? MnX1NlUh|ryP M1PSRVEhcA>? MUDicJVvfHNidHjlJGJc[V2SLXnu[JVk\WRiaX7jdoVie2ViaX6gdIhwe3Cqbz3DbIsyKGGwZDDwbI9{eGixLVXST{BmgHC{ZYPzbY9v NXnrdVdpOjV5NkmxPFE>
MCF-7  MlfQSpVv[3Srb36gRZN{[Xl? MojaNVAh|ryP MmG0NUBp MUTpcohq[mm2czDJUE0yQC2nbnjhcoNm\CClZXzsJI1q\3KjdHnvci=> NULMSmJvOjV5MkewNVE>
HepG2  MX\GeY5kfGmxbjDBd5NigQ>? NHTx[XQyOCEQvF2= NHzYUHk2KGh? MlH3Zoxw[2u|IIDoc5NxcG:{eXzheIVlKE2DUFvzJIlv\HWlZXSgZpkh\XixZ3Xuc5V{KFSJRj5OtlE> M3HXblI2PTZyNEi4
HepG2  MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViyNEDPxE1? NYnQfYFFOjRiaB?= MV7zeZBxemW|c3XzJHRITi4QskGtbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZY5lKGmwdnHzbY9v NWDZclRyOjV3NkC0PFg>
MDA-MB-231 M3TYdmZ2dmO2aX;uJGF{e2G7 MlLENlUh|ryP NF;ZRokzNTNiaB?= MYrk[YNz\WG|ZYOgdE1GWktzL{KgZY5lKFNzMEDBOEBmgHC{ZYPzbY9v MViyOVU2PTh5NR?=
SW480 Ml3xSpVv[3Srb36gRZN{[Xl? M3TVTlIxyqEQvF2= MUGxxsBp NFHl[oxz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGFVTjNicILveIVqdg>? MXOyOVQ1PzhzNh?=
HCT-15 M1vU[WZ2dmO2aX;uJGF{e2G7 M3XVXVEhcA>? NVfzeplW[XS2ZX71ZZRmeyCSR1WyMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzc8Li NILxTVkzPTR|MUSyOS=>
HCT-15 NHXQN21CeG:ydH;zbZMhSXO|YYm= MUixJIg> MoLGZYJwdGm|aHXzJJRp\SCycn;0[YN1cX[nIHXm[oVkfHNib3[gVGdGOsLiYXfhbY5{fCCldYLjeY1qdi2rbnT1Z4VlKGGyb4D0c5Nqew>? NFXjOoIzPTR|MUSyOS=>
786-O MojCRZBweHSxc3nzJGF{e2G7 NHPwRpI2OMLizszN NUe5enE1OjRiaB?= NGL3bGNxd3SnboTpZZRme8LidHjlJJBzdy2jcH;weI91cWNiZX\m[YN1eyCxZjDORy=> M2D2S|I1PTB6NEe2
A498 MVLBdI9xfG:|aYOgRZN{[Xl? NXvBUphQPTEEoN88US=> NYDpTHd6OjRiaB?= NF\ERnBxd3SnboTpZZRme8LidHjlJJBzdy2jcH;weI91cWNiZX\m[YN1eyCxZjDORy=> NF\qcGQzPDVyOES3Oi=>
NHBE MYnGeY5kfGmxbjDBd5NigQ>? MoP3Nk8zOCEQvF2= MlfYNkBp NH:5VopifHSnboXheIV{KEmOLUOzJJN1cW23bHH0[YQhS1iFTEivTWwuQCC|ZXPy[ZRqd25? NEf3Nm0zPDR5OUWyOi=>
A375 NX\YbWtiS2WubDDJcpZie2mxbjDBd5NigQ>? NUnRVmc5OTEkgKOyNEDDvU1? NIe5XYQzPCCq MnjEdoVlfWOnczDt[Yxidm:vYTDj[YxtKGmwdnHzbY9v NGf5PGQzPDR4NkCzOi=>
HBMEC NYqySVBCTnWwY4Tpc44hSXO|YYm= MXWxNEDPxE1? NYLaU2hzOSCq NUfZXmhx[myxY3vzJHZGT0ZvaX7keYNm\CCHcHjBNkBmgHC{ZYPzbY9v M{eyPFI1PDV6OUiy
HPAEpiCs  MYLGeY5kfGmxbjDBd5NigQ>? NVvtc4dNOzBizszN NHLOcZYyKGh? NWS0TW1ucW6qaXLpeJMhXE6ILd8xJJN1cW23bHH0[YQheDR{L4C0OEBOSVCNIIDoc5NxcG:{eXzheIlwdg>? NGH4OlMzPDR2MUi3NC=>
BeWo NWTiU3JOTnWwY4Tpc44hSXO|YYm= NIXDSm4yOMLizszN M{X5TFIhcA>? NVnjOIFTcW6qaXLpeJMhTVKNMT:y MkPoNlQ1OzN6NE[=
PC3  NGPPNmhCeG:ydH;zbZMhSXO|YYm= MkTXOVAh|ryP NIPkVlQxNjViaB?= NVW2WJVRcW6qaXLpeJMhVUi\LUS0PU1qdmS3Y3XkJIFxd3C2b4Ppd:Kh NYfNXYZFOjR2MkS4PFk>
HGC-27 M33XSmFxd3C2b4Ppd{BCe3OjeR?= NYDRcFU4OSEEtV2= MkL1NUBp NVfwTWhCe3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:|cx?= MVqyOFQyPjN2OR?=
MCF-7 NILKNo9HfW6ldHnvckBCe3OjeR?= NHSzW2YyOMLizszN NITvOnkyOC9|MDDtbY4> Mn61doVlfWOnczD0bIUhXVSSLXTldIVv\GWwdDDFVmsheGixc4Doc5J6dGG2aX;u MoWxNlQ{QTB6MUm=
HUVECs NInWcWlHfW6ldHnvckBCe3OjeR?= MkPpNVDDqM7:TR?= M4rJOVEhcA>? M1HFfIlvcGmkaYTzJJRp\SCKRFygdoVlfWOnZDDDU3guOiCneIDy[ZN{cW:wIHHu[EBRT0lvMjDy[Yxm[XOn NHvwXFAzPDN6NUGwPS=>
HeLa MnvSSpVv[3Srb36gRZN{[Xl? MXG1NEDPxE1? MXywMlUhcA>? M4\JToJtd2OtczDUVnguOSCwdXPs[YFzKG2rZ4LheIlwdiCjbnSgWHhPUVBiZH;3ck1z\We3bHH0bY9v NV7oVHVsOjR|N{[4Nlc>
HL-60  M2LiOGZ2dmO2aX;uJGF{e2G7 MX:xNE8zOCEQvF2= MVqxJIg> M3nRZYlvcGmkaYTzJJRp\cLiTj6gZ4hqdmWwc3nz[Zh1emGldNMgbY5lfWOnZDDkbYZn\XKnboTpZZRqd25iaX70c{BoemGwdXzvZ5l1\XN? NULUR5pYOjR|NUewNlA>
HL-60 M4Gyd2Z2dmO2aX;uJGF{e2G7 M4T6bFIhyrWP NVLZOYdlOTZiaB?= MXTEUXNQ M2rnNIlvcGmkaYTzJJRp\SCjc4PvZ4lifGmxbjDv[kBxWzZ{MTDSZYYuOSCjbnSgUmZCXGN|LDDhcoQhfGinIGLBMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJI52[2ynYYKgUmZCXGN| MnvTNlQ{OzByNki=
HEK 293 M1[wWGZ2dmO2aX;uJGF{e2G7 MnXhNVAh|ryP MlnlOUBp NGf1NYFFVVOR MV\pcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36= NYToSWlQOjR|MkSzOlY>
HEK 293 MYPGeY5kfGmxbjDBd5NigQ>? M2Ww[|ExKM7:TR?= NWO1UIltPSCq M17tW2ROW09? MVjzeZBxemW|c3XzJJRp\SCFUmSgZYN1cX[rdIm= NXXO[I5IOjR|MkSzOlY>
SW480 NEPMZodHfW6ldHnvckBCe3OjeR?= NH3JN2gyOCEQvF2= M3HTSVIxKGh? M4PaNGROW09? NHHIbZJ{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk> NFLTVmUzPDN{NEO2Oi=>
HCSMCs M2K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWxNEDPxE1? M3PXN|I1KGh? NVLjTFJ[[myxY3vzJGZCSlB2LXnu[JVk\WRiSFPBV21EKHC{b3zp[oVz[XSrb36= MX[yOFMyOjN6MR?=
PANC-1 MmDjSpVv[3Srb36gRZN{[Xl? Mk\jNlAh|ryP MWe0PEBp NFL5N3dqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kDPnD[GIHnuJJJme3CxboPlJJRwKHSqZTDQVGFT|rUEoHHnc45qe3UEoB?= NWPNdXp3OjR{OUSxN|M>
A549 NGPs[WJHfW6ldHnvckBCe3OjeR?= NFznbHc{OCEQvF2= NGLLSFkxNjViaB?= NF3YWZdFVVOR MX7pcohq[mm2czD0bIUhfGi{b33ibY4ucW6mdXPl[EBKVC16L1PYR2w5NUy3YzDhZ5Rqfmm2eR?= NH7MOoEzPDJ5N{[5Oi=>
A549 MXTGeY5kfGmxbjDBd5NigQ>? NEHEd2k{OCEQvF2= M17QeVAvPSCq NX3QV2YxTE2VTx?= NYGzTlFScW6qaXLpeJMhfGi{b33ibY4ucW6mdXPl[EBEN0WEUN8yJHRpejJ|NdMgdIhwe3Cqb4L5cIF1cW:w M1nQWVI1Ojd5Nkm2
MC-3 NI\3PGtCeG:ydH;zbZMhSXO|YYm= MYmxNEDPxE1? NH;ST2szPCCq MWrwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m|IHnuJEBk\Wyucx?= M2DBWFI1OjdyNUKz
Raji  Ml[zSpVv[3Srb36gRZN{[Xl? MWGxNEDPxE1? M2O5VlEhcA>? MVTicI9kc3NiaIPCRWZHKGmwZIXj[YQhTXKtMT:yJJBpd3OyaH;yfYxifGmxbh?= NGX3WZgzPDJ4OU[zNC=>
Raji  MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojmNVAh|ryP NXLnOGFYOSCq MX7pcohq[mm2czD0bIUh[mG|YXygc5IhcHOEQV\GMZN1cW23bHH0[YQh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdIm= MYWyOFI3QTZ|MB?=
HT29 NWPsbVVHTnWwY4Tpc44hSXO|YYm= NHLHbI4yOCEQvF2= NFT4PWMzKGh? NXPmOnBRcW6qaXLpeJMhd2ZiSlHLNkwhTVKNMT:yJIFv\CCVVFHUN{BxcG:|cHjvdplt[XSrb36= MmfyNlQzPjV{OUO=
HepG2 MoTHRZBweHSxc3nzJGF{e2G7 MoG2NlAh|ryP MnjSNlQhcA>? MofYbY5pcWKrdIOgSXJMOS9{IIDoc5NxcG:{eXzheIlwdiCjbnSg[Y5p[W6lZYOgWmIyNWmwZIXj[YQh[XCxcITvd4l{ NVnlVXNHOjR{NEe5NFk>
HepG2 NXfaNmNmTnWwY4Tpc44hSXO|YYm= M1rWblIxKM7:TR?= M2\i[lIhcA>? M1nnTIVvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm= NIPGOZIzPDJ2N{mwPS=>
TE4 MXzGeY5kfGmxbjDBd5NigQ>? MXKyNE82OC9zMECg{txO MXG0PEBp M1nrRWROW09? MYHpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXHHNIZvOjR{NESwNlM>
TE1 NHrVOFdHfW6ldHnvckBCe3OjeR?= M2ixSlIxNzVyL{GwNEDPxE1? M1XHdVQ5KGh? NYPv[nhQTE2VTx?= MV;pcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHzmSI8zPDJ2NECyNy=>
KYSE30 M1:zSmZ2dmO2aX;uJGF{e2G7 M{LPSlIxNzVyL{GwNEDPxE1? MX[0PEBp NV;pNWFPTE2VTx?= M3rKSIlvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3;yb|I1OjR2MEKz
TE1 NYj2TYN[TnWwY4Tpc44hSXO|YYm= M{DSd|UxKM7:TR?= MWO0PEBp MV\EUXNQ MV71dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? MUSyOFI1PDB{Mx?=
TE3 NF;qc2lHfW6ldHnvckBCe3OjeR?= NV64TXVwPTBizszN MVK0PEBp NE\yXGdFVVOR MXj1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? NWrheWNOOjR{NESwNlM>
TE4 NIrLem1HfW6ldHnvckBCe3OjeR?= NFHTN482OCEQvF2= M1LPXVQ5KGh? M4jWR2ROW09? MmixeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? M3Hnb|I1OjR2MEKz
TE5 NETIVWNHfW6ldHnvckBCe3OjeR?= M1HuU|UxKM7:TR?= M1jsbFQ5KGh? MoXrSG1UVw>? NHTodFh2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?= NETC[XIzPDJ2NECyNy=>
KYSE30 NUHWd2NxTnWwY4Tpc44hSXO|YYm= NXTiO5RbPTBizszN NV3FZW1DPDhiaB?= M3vrSmROW09? MU\1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? MWSyOFI1PDB{Mx?=
MKN7 Ml7ZSpVv[3Srb36gRZN{[Xl? NGnsUIc2OCEQvF2= MojoOFghcA>? NVvuV3ByTE2VTx?= Ml3HbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= NEDBN5YzPDJ2NECyNy=>
OE19 MWrGeY5kfGmxbjDBd5NigQ>? NGfESlY2OCEQvF2= MX20PEBp M372cWROW09? MnPPbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= NYDXXoNuOjR{NESwNlM>
KATOIII  NY\GW2ZoTnWwY4Tpc44hSXO|YYm= MnO3OVAh|ryP NGDYSpI1QCCq MVfEUXNQ NVrtO2ZOcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NYDLU|Q{OjR{NESwNlM>
NCI-N87  MU\GeY5kfGmxbjDBd5NigQ>? MXu1NEDPxE1? MYW0PEBp MXTEUXNQ MoS1bY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= NID5c24zPDJ2NECyNy=>
NUGC3 M13sS2Z2dmO2aX;uJGF{e2G7 M2r5XFUxKM7:TR?= M{HLPFQ5KGh? NE\zXW9FVVOR M1f0TIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO= NHz6d5AzPDJ2NECyNy=>
NUGC2 MXLGeY5kfGmxbjDBd5NigQ>? MXK1NEDPxE1? MYK0PEBp MXfEUXNQ NFHhXoJqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz M{TzU|I1OjR2MEKz
SGC-7901  MkXDRZBweHSxc3nzJGF{e2G7 NE\KXYQzOCEQvF2= MlO1NlQhcA>? NFv5WXlqdmirYnn0d{BEWC2vZXTpZZRm\CCjcH;weI9{cXN? MVKyOFI1OTN3MR?=
MG-63 MX7GeY5kfGmxbjDBd5NigQ>? M33UOVIxKM7:TR?= MV6wMlUhcA>? NHfIS5hjdG:la4OgeIhmKEOKLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQhTUyNMTDwdo91\WmwIHX4dJJme3Orb36= NWi0[mZCOjR{M{m2OFA>
ARPE-19 MXLGeY5kfGmxbjDBd5NigQ>? MV[yNEDPxE1? NHjFdosxNjViaB?= MmPQbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0 MX2yOFIzPzlzOB?=
CRL-2302 M3HjTWZ2dmO2aX;uJGF{e2G7 MVeyNEDPxE1? MUewMlUhcA>? M1L5bIlvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=> M4jMS|I1OjJ5OUG4
MCF-7 NHzDN4VHfW6ldHnvckBCe3OjeR?= NF3Jd5gzOCEQvF2= NITWRokyKGh? MVXhZo9tcXOqZYOg[ZhxemW|c3nvckBw\iCyaH;zdIhwenmuYYTl[EBGWktiY3:teJJm[XSvZX70JJdqfGhiY3;ubpVo[XSn M2X0TVI1OjF4Mki5
MCF-7 MlHsRZBweHSxc3nzJGF{e2G7 M2TkXlIxKM7:TR?= NXHQNW5qOSCq NXvNd21vcW6lcnXhd4V{KGOjc4Dhd4UuQSCnbor5cYUh[WO2aY\peJk> NHzYcmQzPDJzNkK4PS=>
DLD-1  M4fBXGZ2dmO2aX;uJGF{e2G7 NHrwPGozOMLizszN M4Owc|Q5KGh? MoTldoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD M4nBV|I1OjFzNUix
HT-29 M{XFUmZ2dmO2aX;uJGF{e2G7 NUfQenBVOjEEoN88US=> Mny2OFghcA>? MXLy[YR2[2W|IITo[UBDVkmSMzDlfJBz\XO|aX;uJJBz\S22cnXheIVlKHerdHigOU1igmFvZFO= MlrXNlQzOTF3OEG=
7402 NFqxdHdCeG:ydH;zbZMhSXO|YYm= NV;3U3FCOzBizszN NYO5N4p4PSCm NWfzZVRo\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MnjINlQzOTF{NUO=
7721 M1;ONmFxd3C2b4Ppd{BCe3OjeR?= MUizNEDPxE1? M2PnS|Uh\A>? M{LX[IRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> Ml;6NlQzOTF{NUO=
SGC7901  NVfaUmNmSXCxcITvd4l{KEG|c3H5 NXzlUm5jPTEEoN88US=> MlLsNlQwPDhxN{KgbC=> MU\EUXNQ NGm1eGFqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT|Ihe2iUTlG= MUmyOFE4QDJ2MB?=
SMMC7721 MWTGeY5kfGmxbjDBd5NigQ>? NHfjPHYzPS93MDFOwG0> NXLKO5V[OjRiaB?= MUXzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSWu2IH;yJJAuTVKNMT:yxsA> M1HVTVI1OTZ6MEW2
MCF-7 NHi1OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWyNVAh|ryP MkPUOFhp MUPEUXNQ M2DYUJJmfmW{c3XzJGJPTi2rbnT1Z4VlKGOnbHygZ5lkdGViYYLy[ZN1 MXqyOFE3OzRyNB?=
Caco-2 M33pUGZ2dmO2aX;uJGF{e2G7 NIHxbI02OMLizszN NIL4V2Y1QGh? MoLmSG1UVw>? NH3uOXRmdmijbnPld{B1cGVibWLORUBt\X[nbIOgc4bDqFOFTl6xRUxHYFmGMz|CpGxEXC{EoFzPXEzDqEiLRkPBMOKhYkdzNj|CpHBFTT[DwrDhcoTDqEyJQVzTNVbDqGenbnXzxsBkdy22cnXheIVlKHerdHigSIV5 NUTqUFNSOjRzNkG2PVU>
HAECs MWjGeY5kfGmxbjDBd5NigQ>? NI\rfXoyOCEQvF2= M4\uPFEhcA>? MnzSxsBifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKEmFQV2tNUBidmRiVlPBUU0yKGW6cILld5Nqd25? MVOyOFE{PDZ3Nx?=
Ca9-22 NFv6bZJHfW6ldHnvckBCe3OjeR?= NVrtNoFwOyEQvF2= MlvmNUBp NXjSR2p{[WKxbHnzbIV{KHSqZTDhZoltcXS7IH;mJGhjWiC2bzDpcoR2[2ViSVytPEBxem:mdXP0bY9v Mln2NlQyOjZ3M{K=
Ca9-22 M37oPGZ2dmO2aX;uJGF{e2G7 Mn7qN{DPxE1? MWSxM|IhcA>? MXHy[YR2[2W|IFjiVk1qdmS3Y3XkJGFVTi1{IIDoc5NxcG:{eXzheIlwdg>? NWrSOnJlOjRzMk[1N|I>
AGS NVLibog{TnWwY4Tpc44hSXO|YYm= NILjZmsyOCEQvF5CpC=> MWiwMlUhcA>? MoKxbY5pcWKrdIOgeIhmKHWycnXneYxifGmxbjDv[kB1cGViSVytPEBo\W6n Mn;0NlQyODZzNk[=
Caco-2  NXPjfYhFSXCxcITvd4l{KEG|c3H5 M4Wyc|ExyqEQvF2= M363OlI1yqCq M2LZW4Rm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV? MUeyOFA6PTh4Mx?=
HCT-8 MYfBdI9xfG:|aYOgRZN{[Xl? NXvvUoN1OTEEoN88US=> NGO2bHMzPMLiaB?= M{DafoRm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV? NGT1SYMzPDB7NUi2Ny=>
A549 NWjrbYdSTnWwY4Tpc44hSXO|YYm= NXLleFhsPTEEoN88US=> NGLZOoszKGh? M{jsTYJtd2OtczDFVmsheGixc4Doc5J6dGG2aX;uJI1m\GmjdHXkJIJ6KDFuMj3OVS=> NVewS2lLOjRyNke3Nlc>
HPMC MlGzSpVv[3Srb36gRZN{[Xl? NFPSZpgyOMLizszN MnnSOFghcA>? MYjy[ZZmenOnczD0bIUh[2ijbnfld{BqdiClZXzsJI1wenCqb3zv[5khcW6mdXPl[EBjgSCKR2DEVy=> M3vVWVI1ODR{OEO4
HPMC M4X2S2Fxd3C2b4Ppd{BCe3OjeR?= MUmxNOKh|ryP NXjVSmdUOjUEoHi= NF7wW5Fz\X[ncoPld{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KEiJUFTT M2Tse|I1ODR{OEO4
MGC803  NEGxOmRCeG:ydH;zbZMhSXO|YYm= MUWyNOKh|ryP MoXPNUBp MmDybY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU M4XZclI1ODJ5N{Ww
SGC7901 M1nrdWFxd3C2b4Ppd{BCe3OjeR?= M1jGOFIxyqEQvF2= MVWxJIg> M{fuUYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?= NXP3Vmk5OjRyMke3OVA>
COLO205 MkTKRZBweHSxc3nzJGF{e2G7 NET1RXYyOC9{MD:0NEDPxE1? M{HO[FI1KGh? MXvpcoR2[2W|IFTORUBt[WSmZYKg[o9zdWG2aX;u MYWyOFAyQTFyOB?=
G292  M4ToVWFxd3C2b4Ppd{BCe3OjeR?= MnfWN|DDqM7:TR?= NE\o[pYzKGh? MXXy[ZN1d3KnczDjZZB{[WmlaX6tbY5lfWOnZDDj[YxtKGSnYYTo NHexeHQzPDBzMkmzNC=>
BxPC-3 MkLqSpVv[3Srb36gRZN{[Xl? MnLPNVAh|ryPwrC= NVzWOGQxPiCq MlTRbY5kemWjc3WgcYlTNTF2MzDlfJBz\XO|aX;u M{P2fFI{QTd|N{Gw
HPAF-II MoLHSpVv[3Srb36gRZN{[Xl? MXWxNEDPxE4EoB?= M3zkS|YhcA>? MWTpcoNz\WG|ZTDtbXIuOTR|IHX4dJJme3Orb36= M3fiOlI{QTd|N{Gw
HL-60 MX\BdI9xfG:|aYOgRZN{[Xl? M1GzXlUxyqEQvF2= NXqwNFZGOSCq NYr2TXhiemW|Y4Xld{BDSTF2NTDt[YRq[XSnZDDhdI9xfG:|aYO= Ml3GNlM6PDh5NUG=
HepG2 M2n3R2Z2dmO2aX;uJGF{e2G7 MW[0NEDPxE1? NUL2XIxsPi9zMjDo MWrpcohq[mm2czD0bIUhcW6lcnXhd4Uhd2ZicD3FVmsyKGGwZDDwMYMuUnWwIIDyc5RmcW5iZYjwdoV{e2mxbjDifUBRVA>? NV61fIJIOjN7NEK4OVE>
HUVECs Mom4SpVv[3Srb36gRZN{[Xl? MXuyOUDPxE1? NXjseFlJOSCq NEm1S2RqdmO{ZXHz[UBPTi4QulKgdFY2KG63Y3zlZZIhfHKjboPsc4NifGmxbh?= M3TreFI{QTBzMEC4
LNCaP  MmP2SpVv[3Srb36gRZN{[Xl? MYqxNEDPxE4EoB?= NXXHTVd1OSCq Ml\J[IVkemWjc3XzJJRp\SCHR1[geZBz\We3bHH0[YQheC2\Qj2x NH3j[28zOzh|OEOxPC=>
HL60  M3nDUmZ2dmO2aX;uJGF{e2G7 NYm2WmNDOjEEoN88US=> M4\hflczKGh? NWnqfWx7TE2VTx?= MVzpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w MoPENlM5OjV3OEW=
NB4  MYXGeY5kfGmxbjDBd5NigQ>? MXqxNEDPxE4EoB?= M4\qS|czKGh? MXPEUXNQ NX6wWYJvcW6qaXLpeJMh\GG|YYTpcoljNWmwZIXj[YQhS0RzMXKg[ZhxemW|c3nvci=> M1HEVlI{QDJ3NUi1
EPOR/CR3 NHHONZNHfW6ldHnvckBCe3OjeR?= MXi1NOKh|ryP NGXUR2c{KGh? MlPpdoVlfWOnczDFVG8h[W6mL3;yJGlNNTNvaX7keYNm\CC2aHWgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wwrC= M3ju[FI{QDJyN{Ox
HUASMCs NH2wTpFHfW6ldHnvckBCe3OjeR?= NWPJWXV{OTBizszNxsA> NXfLNHRROjRiaB?= NEniNpdlcW2rbnnzbIV{KEGwZzDJTU1k[XW|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC= M4e5TVI{QDF4NE[4
HUASMCs NHi1O5ZHfW6ldHnvckBCe3OjeR?= NWq1NYpNOTBizszNxsA> NH7KTVYzPCCq MoDHbY5pcWKrdIOgRY5oKEmLLXnu[JVk\WRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBt\X[nbB?= MYKyN|gyPjR4OB?=
SGC7901 MX3GeY5kfGmxbjDBd5NigQ>? NXu3dXI3OTBizszNxsA> M333OlI1KGh? NIrBZnBqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ? M3H4blI{Pzl{NUi4
MKN45 M2fHb2Z2dmO2aX;uJGF{e2G7 M122TVExKM7:TdMg MV6yOEBp M{HiO4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST|EwOg>? M1y0TFI{Pzl{NUi4
SGC7901 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[wVFExKM7:TdMg MXeyOE81QC95MjDo NYTxS|NXcW6qaXLpeJMh[2WubDDndo94fGhiY3:teJJm[XSnZDD3bZRpKESDUGS= MX2yN|c6OjV6OB?=
MKN45 NVLOSZlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxNEDPxE4EoB?= M37meVI1NzR6L{eyJIg> NIfmeHBqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?= NGjHcIszOzd7MkW4PC=>
SGC7901 NXXoVoxESXCxcITvd4l{KEG|c3H5 NX3DU2s4OTBizszNxsA> M4rnVlI1KGh? MoHrbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? MnvnNlM4QTJ3OEi=
MKN45 NX7LVGZySXCxcITvd4l{KEG|c3H5 NFSzWWcyOCEQvF5CpC=> NHGyZ3ozPCCq MnrwbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? MmDENlM4QTJ3OEi=
BxPC-3 cells M3T6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr5RWszOMLizszN MU[wMlUhcA>? MkTMbY5pcWKrdIOgWmVITi2DLYLl[5Vt[XSnZDDIWXZGSyCpcn;3eIgh[W6mIIT1ZoUh\m:{bXH0bY9vKGmwZIXj[YQh[nliUFHSMVIhSVB? M1PwcFI{PzZ2MES2
NB4  NH\RWpdCeG:ydH;zbZMhSXO|YYm= M{e1bVExNzJyL{[wJO69VQ>? M2HGVVEvPSCq MVXEUXNQ NYHmZnR[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDQZYNtcXSjeHXs MmfQNlM4OzV3NEG=
HepG2  NGLWNpBHfW6ldHnvckBCe3OjeR?= MkizNlDDqM7:TR?= MmXENlQhcA>? NWLnSWxRcW6qaXLpeJMhfGinIFjPMVEheHKxdHXpckBmgHC{ZYPzbY9vKGOxLYTy[YF1\WRid3n0bEBu\XSob4LtbY4> NWnKS4tZOjN5MEe2NFk>
HUVECs MYHBdI9xfG:|aYOgRZN{[Xl? MmHaNk81KM7:TR?= MmrENlQwPDhiaB?= MnTjbY5lfWOnczDj[YxtKGSnYYTo NV\1WIF1OjN5MEe1NlA>
KG-1  MnflRZBweHSxc3nzJGF{e2G7 NGXCOFIzOMLizszN NYLRNodHOTJiaB?= MkPS[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=> M{HrWlI{PzB4Nkmx
AML 1# NUPMXFljSXCxcITvd4l{KEG|c3H5 NE\JPG0zOMLizszN MWWxNkBp MWPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx MVqyN|cxPjZ7MR?=
A2780  Mo\4SpVv[3Srb36gRZN{[Xl? NEDISFgzOMLizszN NYX2dW5zOSCq M3\keYJtd2OtczDEWGNFNWmwZIXj[YQhTFJ3IHX4dJJme3Orb36= NXmweVFbOjN4OU[4OlI>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; 

PubMed: 17482134     


ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading.

p-JNK / JNK / Cyclin D1 ; 

PubMed: 17482134     


Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading.

p-HER2 / HER2 ; 

PubMed: 24244023     


TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. 

MMP9 / XIAP / VEGF ; 

PubMed: 29695559     


SK-Hep1 cells were treated 10 μM PD98059 for 48 h.  Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.

17482134 24244023 29695559
In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID